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Effect of cholecystectomy on bile acid
 synthesis and circulating levels of fibroblast growth factor 19
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ABSTRACT
Background and rationale for the study. FGF19/15 is a gut-derived hormone presumably governing bile acid
(BA) synthesis and gallbladder (GB) refilling. FGF19 mRNA is present in human GB cholangiocytes (hGBECs);
however, the physiological significance of GB-derived FGF19 remains unknown. We investigated whether
hGBECs secrete FGF19 and the effects of cholecystectomy on serum FGF19 ([FGF19]s) and BA synthesis.
Material and methods. FGF19 expression was assessed by qRT-PCRs and immunostaining in hGBECs and
terminal ileum, and quantified in bile and serum by ELISA. Basal and BA (chenodexycholic acid, CDCA) induced
FGF19 expression and secretion was analyzed in primary cultured hGBECs and GB-d1 cell line. Pre and pos-
tprandial serum changes in [FGF19]s, 7D-hydroxy-4-cholestene-3-one (C4, a marker of BA synthesis) and BA
were evaluated in plasma of gallstone disease patients at baseline and after cholecystectomy. Results.
FGF19 mRNA levels were ~250-fold higher in hGBECs compared to distal ileum. GB bile contained ~23-fold
higher FGF19 levels compared to serum (p < 0.0001). CDCA induced dose-dependent expression and secre-
tion of FGF19 in hGBECs and GB-d1 cells. Cholecystectomy increased plasma BA synthesis t 2-fold (p <
0.0001), and altered the diurnal rhythm and significantly reduced [FGF19]s noon peak. BA serum levels,
serum cholesterol and triglyceride content remained unchanged. Conclusions. In conclusion human GB
cholangiocytes constitutively express and secrete high levels of FGF19 in a process regulated by BA.
Resection of this organ doubles BA synthesis concomitantly with changes in [FGF19]s. These findings suggest
a potential connection between GB cholangiocytes-derived FGF19 and BA metabolism that could lead
to metabolic dysregulation following cholecystectomy.
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ORIGINAL ARTICLE
KEY POINT BOX
 FGF19 is highly expressed and secreted in human
gallbladder and its secretion is stimulated by
chenodeoxyxholic acid, a natural farnesoid X
receptor ligand.
 In subjects with cholesterol gallstone disease,
gallbladder cholangiocytes FGF19 expression is
significantly reduced.
 Cholecystectomy modifies serum FGF19 diurnal
rhythm by inducing a significant reduction on its
noon peak. These changes are associated with
a two fold increase in C4, a bile acid synthesis
biomarker.
 Taken together these findings suggest gallbladder
has an important function in BA homeostasis
regulation, probably mediated by FGF19 secretion.
INTRODUCTION
The human fibroblast growth factor 19 (FGF19)
is considered an atypical member of the fibroblast
growth factor protein family. Similar to FGF21 and
FGF23, FGF19 shows reduced affinity to bind
heparin, which allows it to diffuse and act as an en-
docrine hormone.1 FGF19 functions have been
mainly explored on its mouse ortholog Fgf15.2-4
© 2019, Fundación Clínica Médica Sur, A.C. Published by Elsevier España S.L.U. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In gut this protein is produced mainly by ileum ente-
rocytes, where its expression is induced by bile acids
(BA) signaling through the farnesoid X receptor
(FXR). Ileum derived FGF19/Fgf15 is presumably
transported to the liver through the portal system
where it ultimately suppresses BA synthesis.2,5 Ad-
ministration of high doses of recombinant FGF19 to
human hepatocytes, or to mice, inhibits BA synthe-
sis through repression of cholesterol 7-alpha-hy-
droxylase (CYP7A1), the first and rate-limiting
enzyme in the classical BA biosynthetic pathway.6 In
addition, FGF19/Fgf15 stimulates gallbladder (GB)
refilling in mice by a cAMP mediated smooth muscle
cells relaxation.3 In humans, correlative evidence
arising from a few recent studies supports a funda-
mental role of FGF19 as a gut derived hormone con-
trolling BA synthesis.7-10 While the above data
strongly support that FGF19/Fgf15 is a complemen-
tary pathway participating in the postprandial nega-
tive feedback loop for BA homeostasis and GB
motility, more data is needed to obtain more insight
about the role of FGF19 as metabolic regulator in
humans.11
Recent data suggest that FGF19 may also be in-
volved in the modulation of metabolic syndrome.12,13
Animal models exposed to supra physiologic levels of
recombinant FGF19 show reduced body weight and
adiposity, and are less prone to develop dyslipidemia,
hepatic steatosis, hyperinsulinemia, hyperleptinemia
and insulin resistance.14,15 Mechanisms known to
participate include increased energy expenditure and
fatty acid oxidation. Thus, FGF19 mediated path-
ways could play key roles in human metabolism be-
yond BA homeostasis.16
FGF19 was first cloned and described by Xie, et
al., who demonstrated by in situ hybridization its
mRNA transcripts in a variety of human tissues in-
cluding adult GB epithelium.17 Since cholangiocytes
constitute an essential part of the entero-hepato-bil-
iary axis with relevant implications in gastrointesti-
nal physiology we aimed to:
 Explore if FGF19 is synthesized and secreted by
human GB cholangiocytes.
 Investigate whether FGF19 synthesis and secre-
tion in human cholangiocytes is regulated by the
FXR natural ligand chenodeoxycholic acid
(CDCA), and
 Explore the effect of cholecystectomy (CCT) on
FGF19 serum levels and BA metabolism.
In addition, we evaluated whether the expression
level of FGF19 in normal GBs differs from GBs of
patients with cholesterol gallstones, the most preva-
lent biliary disease in western countries.
MATERIAL AND METHODS
Collection of human samples
Informed consent was obtained from all subjects
included in this study. Experiments using human
samples were conducted according to the ethical
guidelines of the 1975 Declaration of Helsinki as re-
flected in a priori approval by the Institutional Re-
view Board of the Faculty of Medicine at the
Pontificia Universidad Católica de Chile. We collect-
ed biopsies from macroscopically normal duodenal
(2nd to 3rd segment; n = 14) and terminal ileum
mucosa (5 to 10 cm proximal to the ileocecal valve,
n = 15) donated by subjects in outpatient clinic un-
dergoing endoscopy or colonoscopy for symptoms of
common non-malignant and non-inflammatory dis-
eases. Four biopsies per patient were taken; one was
fixed in formalin and examined histologically and 3
were snap frozen in liquid nitrogen and maintained
at -80 °C until further analysis. Cases with his-
topathological alterations were excluded from the
study.
Human GB tissue and bile specimens were ob-
tained from non-obese adult subjects undergoing
elective CCT essentially as described.18 We recruited
prospectively recruited 8 patients with cholesterol
gallstone disease (GSD) and 8 control GSD-free sub-
jects who underwent incidental CCT during liver
(focal lesions), pancreatic (tumors) or gastric (gas-
tric cancer) surgery. Subjects with clinical or labo-
ratory evidence of hepatic, kidney or intestinal
disease, or taking medications known to alter lipid
metabolism were excluded. Additional exclusion cri-
teria for GSD patients were presence of large gall-
stones (> 20 mm), multiple gallstones filling more
than 30% of GB lumen or recent event of biliary-re-
lated pain (< 1 week from recruitment). Fragments
of the freshly excised GBs were frozen in liquid ni-
trogen and stored at -80 oC until use. Additional
fragments were fixed in formalin, embedded in paraf-
fin, sectioned at 5 m, and stained with hematoxy-
lin-eosin. Most of GB specimens were used to isolate
primary hGBECs through a combined enzymatic/me-
chanical procedure as previously described.19 Micro-
scopic examination of an aliquot of freshly isolated
hGBECs revealed that more than 95% of cells had
epithelial features. HGBECs were frozen in liquid ni-
trogen and kept at -80 °C for subsequent protein and
RNA extraction as described below. Some fresh
Barrera F, et al , 2015; 14 (5): 710-721
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harvested hGBECs samples were immediately proc-
essed for primary culture experiments.
Cell isolation, culture and treatment
Fresh hGBECs were isolated from gallstone free
subjects and cultured as detailed elsewhere.20 GB-d1
cells, a human gallbladder carcinoma derived cell
line21 (generously provided by Dr. Juan Carlos Roa,
Universidad de la Frontera, Temuco, Chile), were
cultured in the same conditions as described for hG-
BEC. For details see Supplementary Materials. To
study the role of FXR in the regulation of FGF19,
hGBEC and GB-d1 cells were treated with CDCA, a
potent natural ligand of FXR.22 All media were sup-
plemented with 10% FBS unless otherwise specified.
Cells were first cultured with BA-depleted medium
(DMEM with 10% FBS charcol-dextran) for 16 hrs.
Subsequently, the culture medium was changed and
cells were incubated for 24 h with 50 M or 100 M
CDCA in 0.1% DMSO. Control cells were incubated
with vehicle only. Then, cells were harvested for im-
munostaining and reporter gene assays. The super-
natant was kept at -80°C for FGF19 quantification.
For details see Supplementary Material and Meth-
ods section.
Prospective follow up study in patients
with GSD undergoing elective cholecystectomy
To evaluate the effect of GB resection on FGF19
serum levels and BA metabolism, a cohort of 10 con-
secutive GSD patients undergoing elective CCT and
meeting the inclusion criteria (see Collection of hu-
man samples) were included. Patients underwent a
functional ultrasound GB study, as described else-
where.23 Only patients with normal GB emptying ca-
pacity (ejection fraction > 50%), were included.
Resected GB presented only minor-to-moderate
chronic cholecystitis on biopsy and cholesterol gall-
stones as defined by cholesterol content of > 60% of
dry weight. All subjects were studied at baseline
(visit 1), 14 days (visit 2) and 90 days after CCT
(visit 3). Each time, subjects were evaluated after
overnight fasting and received a standardized break-
fast (Ensure plusMR, 355 Kcal, 50.5 g carbohydrates,
11 g fat and 13.5 g protein) (AbbottMR, IL, USA) and
lunch (501 Kcal, 85 g carbohydrates, 9 g fat and, 22
g protein) at 8:05 AM and 12:05 PM, respectively.
Serum samples were taken at 8:00 AM (before
breakfast), 10:30 AM, 12:00 PM (before lunch), 1:30
PM and 3:00 PM. Serum FGF19, C4, total BA con-
tent, triglycerides and total cholesterol were meas-
ured. All subjects were taking a similar diet and
performing similar physical activity before and after
CCT, according to a 7-day diet history evaluation
and a standardized physical activity questionnaire
(data not shown) by a registered dietitian. The pa-
tients had normal results for fasting liver-function
tests, glucose, serum lipids and insulin during the
follow-up period.
Additional experimental procedures
Detailed descriptions are provided in the supple-
mentary Materials and Methods.
Statistics
Unless otherwise noted, all data are presented as
mean ± SEM. The significance of differences was
tested by two-tailed unpaired or paired (as applica-
ble) t-test using GraphPad Prism 4.03 (GraphPad
Software Inc., San Diego, CA, USA) for Windows.
The level of significance for all statistical analysis
was set at P-value < 0.05. Log-transformation was
performed to normalize FGF19, C4 and total BA
data distribution. Comparison of temporal changes
Table 1. Main clinical characteristics of gallstone disease and control subjects.
GSD Control P value
Number 8 8
Age (years) 36.9 ± 8.1 52.4 ± 15.6 0.03
Gender (female/male) 7 / 1 5 / 5 0.1
Total bilirubin (mg/dL) 0.7 ± 0.3 0.4 ± 0.2 0.08
Alkaline Phosphatases (UI/L) 57.5 ± 7.7 80.9 ± 28 0.07
AST (UI/L) 16.8 ± 3.1 19 ± 6.2 0.4
Cholesterol (mg/dL) 165.7 ± 22.9 180.4 ± 50.7 0.5
Glucose (mg/dL) 85.3 ± 3.4 100.6 ± 20.7 0.1
Data are expressed as mean r SD; mean values were compared using Student´s t test and F2 test. GSD: gallstone disease. AST: aspartate aminotransferase.
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in the follow-up study was performed by one-way
ANOVA with Dunnett’s test, using 08:00 h data as
baseline reference. For comparisons of serum diur-
nal variations of the variables of interest at visits-1,
-2 and -3, and to determine potential interactions of
serum diurnal curves and different study visits, line-
ar mixed effects models24 and generalized estimating
equations (GEE) were used.25 R software was used
for analyses (R Development Core Team 2010).26
RESULTS
FGF19 is abundantly expressed and secreted by
human gallbladder epithelium. The FGF19 mRNA
level was measured in the GB epithelium (n = 15)
and mucosa of terminal ileum (n = 15) and duode-
num (n = 14). Compared with GSD subjects, non-
GSD patients were older but otherwise similar
considering gender, liver-function, serum glucose and
lipids (Table 1). Of note, the FGF19 mRNA level was
~250-fold higher in hGBECs than distal ileum muco-
sa (P = 0.001) (Figure 1B). As expected, FGF19 ex-
pression was 70% lower in duodenal mucosa than in
the terminal ileum. FGF19 protein expression in the
GB epithelium was first demonstrated through immu-
nohistochemistry (IH) and immunofluorescence (IF)
(Figure 1A, negative control in figure 2). A similar
homogeneous and predominant cytoplasmic signal
was observed in both cholangiocytes and enterocytes,
with a fine granular dot-like signal pattern, compati-
ble with vesicular transport and/or storage. Howev-
er, under identical experimental conditions, GB
cholangiocytes exhibited a clearly stronger signal
concordant with the higher mRNA levels. Interest-
ingly, the IF signal for FGF19 in enterocytes was
stronger towards the apical membrane in contrast to
a more basal/lateral type membranous signal pattern
in cholangiocytes (Figure 1A).
Figure 1. Expression of
FGF19 in human gall-
bladder and gut. A. A posi-
tive immunoperoxidase
reaction (IH) and immu-
nofluorescense signal (IF)
for FGF19 protein is evident
predominantly in the cyto-
plasmatic compartment of
gallbladder and distal
ileum epithelia. GB cholan-
giocytes presented a fine
granular dot-like signal
pattern for FGF19 protein
extending from apical
(arrows) to basal domains
(open arrowhead). Ileum
enterocytes showed increa-
sed FGF19 signal towards
the apical cell compart-
ment. Some FGF19 positive
cells were observed in GB
lamina propria, most pro-
bably of myofibroblastic
type (thin arrows). B.
FGF19 expression by qRT-
PCR in hGBECs (n = 15) is
250-fold higher than ileum
(n = 15) and duodenum (n =
14). ** P<0.01 and ‡‡ P <
0.01 compared to ileum
and duodenum respective-
ly. C. FGF19 content in GB
bile (n = 8) is 23-fold higher
than serum levels (n = 45)




























































































Noteworthy, the FGF19 concentration in GB bile
was ~20 fold higher than in serum (20,000 ± 3,400
vs. 880 ± 63 pg/mL, respectively; P < 0.001) (Fig-
ure 1C). No differences in FGF19 concentration was
observed between observed fresh GB bile of GSD pa-
Figure 2. Negative control
for FGF19 immunofluorescen-
ce (IF) and immunohistoche-
mistry (IH) staining in human
gallbladder and ileum.
Figure 3. A. FGF19 mRNA expression levels in human gall-
bladder cholangiocytes (hGBECs) of cholesterol gallstones di-
sease patients (n = 8) is significantly lower compared to
non-gallstone control patients (n = 8) measured by qRT-PCR
and normalized with 18S mRNA gene expression. B. No signifi-
cant differences were observed in FGF19 content in gall-
bladder bile of gallstone and control patients in the same
subjects. *P < 0.05 compared to control subjects. Results are
express as mean ± SEM.
Figure 4. FGFR2, FGFR3 and FGFR4 mRNA expression levels
in (A) human gallbladder cholangiocytes (hGBECs) and (B) duo-
denum biopsies measured by qRT-PCR and normalized with 18S
mRNA gene expression. *P < 0.05 compared to FGFR3 expres-
sion. Results are express as mean ± SEM. ** P < 0.01 compared
to FGFR3 expression. ‡ P < 0.05 compared to FGFR2.
tients (n = 8) and control subjects (n = 8) (Figure
3B). The abundant expression in GB mucosa and its
elevated levels in the bile, suggested a potential func-
tion of FGF19 in the biliary tree and/or gut mucosa.
Hence, the expression level of FGF receptors,
known to be activated by FGF19, was also explored
in hGBECs and duodenal mucosa.27 HGBECs and
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Figure 5. Analysis for FGF19 in human cholangiocyte cultures. Cells were incubated with FBS charcoal-dextran at baseline, fo-
llowed by 50 or 100 õM CDCA added in medium. Negative controls performed omitting the primary antibody. A. Confocal microscopy
revealed a dose-dependent increase in FGF19 signal after CDCA exposure (Scale bars, 20 õm). The pixel density of the fluorescent
signal was quantified as described in method section in (B) GB-d1 (n = 5) and (C) primary hGBECS cultures (n = 5). D. FGF19 expres-
sion (qRT-PCR) and (E) protein quantification in culture media (ELISA) confirm a dose-dependent induction of transcription and se-
cretion in GBD-1 cell cultures. * P < 0.05 and ** P < 0.01 compared to baseline ‡ P < 0.05 and ‡‡ P < 0.01 compared to 50 õM CDCA.
A Control BA 50 Pm 100 Pm
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of FGFR2 and FGFR4, with negligible levels of
FGFR3 (Figures 4A and 4B, respectively).
Induction of FGF19 in
human cholangiocytes by chenodoxycholic acid
To investigate the role of BAs in the regulation of
FGF19 expression and secretion on human cholan-
giocytes, we treated primary cultured hGBECs and
GB-d1 cells with CDCA, a potent natural ligand of
FXR, and assessed the mRNA and protein FGF19
expression levels and secretion. Because of the ele-
vated basal FGF19 expression in the primary hG-
BECs (Figure 1A), cells were first cultured in
BA-depleted medium to reduce the FGF19 expres-
sion. The BA depletion resulted in a marked reduc-
tion of FGF19 expression in hGBECs (Figure 5A),
whereas CDCA (50 and 100 M) prominently in-
creased FGF19 mRNA and protein levels in a dose-
dependent manner in both, hGBEC and GB-d1 cells.
As shown in figures 5A-5C, treatment with CDCA
caused a robust dose-dependent increase in intracel-
lular fluorescent signal for FGF19 in both GB epi-
thelial cells. There was also a prominent
dose-dependent induction of FGF19 mRNA expres-
sion by about 45-fold (Figure 5D). Moreover, FGF19
protein was actively secreted into the culture medi-
um and CDCA treatment induced a three- to eight-
fold dose-dependent increase in FGF19 secretion in
GBD-1 cell cultures (control 1,593 ± 165 pg/mL vs.
CDCA 50 M 5900 ± 351 pg/mL, and CDCA 100 M
12,545 ± 767 pg/mL, P < 0.01) (Figure 5E). Taken
together, these results confirm that FGF19 is con-
stitutively expressed and secreted by hGBECs under
a BA-mediated signaling mechanism, probably
through FXR as has been shown for other epithelial
cells of the gastrointestinal tract such as entero-
cytes and hepatocytes.6,22,29
Surgical resection of the GB
changes FGF19 serum levels and BA synthesis
To assess the physiological relevance of FGF19
expression in the GB mucosa, we designed a pro-
spective follow-up study in GSD patients undergoing
elective CCT. GSD patients showed a 70% lower ex-
pression of FGF19 in hGBECs compared to control
subjects (Figure 3A), although this expression level
is still ~70-fold higher than in terminal ileum (data
not shown) permitting GSD patients to be a good
clinical model for studying the effect of CCT on
circulating levels of FGF19 and its potential meta-
bolic consequences. The baseline characteristics of
the 10 patients included in this prospective cohort
are listed in table 2. We designed a protocol aimed to
evaluate the effect of GB resection on basal and
postprandial serum levels of FGF19, C47,30,31 and to-
tal BA. Serum levels of FGF19 and C4 are shown in
figures 6A and 6B, respectively. Prior to surgery
FGF19 and C4 levels showed significant daily
changes with a major peak at noon. Interestingly,
GEE ANOVA analysis demonstrated significant dif-
ferences between baseline, 14 days and 90 days after
CCT (P < 0.01). For further analysis we conducted
a GEE regression analysis that demonstrated no sig-
nificant slope at baseline visit (P = 0.08), compared
to a significant slope at 14 and 90 days after CCT
(P = 0.002 and P < 0.001, respectively). These anal-
ysis showed that CCT changed the diurnal rhythm
of circulating FGF19 as early as two weeks after
surgery. Furthermore, FGF19 serum levels tend
to decline three months after CCT, reaching sta-
tistical significance at noon (1,086 ± 114 pg/mL
vs. 651 ± 115 pg/mL P = 0.02). Same results were
obtained after conducting a pairwise ANOVA anal-
ysis with Hochberg multiple comparison post-hoc
test (P = 0.04). Moreover, fasting C4 levels were
consistently increased by more than two-fold as
early as 2 weeks after surgery (33.3 ± 6.2 vs. 91.2
± 12.2 nM, P d 0.01) with a declining curve dur-
ing the day, which differs significantly compared
to baseline (Figures 6B and 7). This change in the
C4 daytime curve remained similar three months
after CCT. Interestingly, FGF19 was related
inversely to BA synthesis (C4) before CCT (R2 =
0.18, P = 0.004), but this correlation was lost
af ter CCT (Figure 8) .  Similar results  were
observed after adjusting C4 levels for total serum
Table 2. Main clinical characteristics of gallstone patients un-




Gender (female:male) 9 :1
Gallbladder ejection fraction (%) 64.3±8.1
BMI (kg/m2) 23.5±1.5
Total bilirubin (mg/dL) 0.6±0.3




Total cholesterol (mg/dL) 183±27
Triglycerides (mg/dL) 137±81
Values are expressed as mean r S.D.BMI: Body mass index. AST: asparta-
te aminotransferase. HOMA-IR: homeostasis model assessment of insulin
resistance.
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Figure 7. Fasting serum C4 levels at baseline and follow up
at (A) 14 days after cholecystectomy (CCT) and (B) 90 days



























































Baseline 14 days post-CCT
cholesterol. Total serum BA did not significantly
change after CCT as compared with preoperative
values (Figure 6C).
DISCUSSION
The results of the present study identify human
GB cholangiocytes as a major source of FGF19. High
FGF19 mRNA levels, together with positive immu-
nostaining and a similar cytoplasmic pattern to distal
ileum enterocytes were detected in hGBECs. This was
accompanied with an elevated concentration of
FGF19 protein in GB bile. Furthermore, we demon-
strated that this expression was induced in a dose-de-
pendent manner by CDCA in human GB derived
cholangiocytes, indicating a BA induced synthesis
and secretion, most probably mediated by activation
of the nuclear receptor FXR.6,22,29 Zweers, et al.28 re-
cently reported similar findings using cultured tissue
explants from GBs and common bile ducts. These re-
sults and the present observations indicate an active
Figure 6. Changes in FGF19 serum levels and bile acid syn-
thesis after cholecystectomy (CCT). A. Levels of FGF19. B. BA
synthesis (C4) and (C) total serum BA at baseline, 14 and 90
days after CCT in ten patients with GSD. Blood samples were
collected after 8 hrs fasting at 8:00 h, and after standardized
breakfast (10:30, 12:00 h) and lunch (13:30 and 15:00 h).
Standardized meals were provided after 8:05 and 12:05 h.
Data are expressed as mean ± SEM. * P < 0.05 and ** P < 0.01
at 14 days after CCT compared to baseline; ‡ P < 0.05 90 days
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secretion of FGF19 by cholangiocytes into bile and
consequently to intestine, representing a potential in-
traluminal signaling pathway between these systems.
However, the functional role of biliary FGF19 re-
mains to be elucidated.28
Since human cholangiocytes and enterocytes ex-
press FGFRs, biliary FGF19 may participate in di-
verse processes, such as tropism and defense of
epithelial cells against bile acid mediated apoptosis,
and regulation of GB and intestinal motility.3
FGF19 has also been involved in regulation of api-
cal sodium bile transfer protein (ASBT) expression
in human gallbladder, ileum and human cholangi-
ocytes cell lines.29
Recent studies have described an oncogenic role
for FGF19 in colon cancer, thus theoretically after
its transit through small bowel, bile-derived FGF19
might promote malignant transformation in colono-
cytes.32 However, before its arrival to colon, bile is
mixed with chymus and undergoes enzymatic diges-
tion. As consequence luminal FGF19 concentration
is significantly reduced. In addition, colon cancer
cells have been described to synthesize and secrete
FGF19 in an autocrine manner.32 In contrast to
colonocytes, cholangiocytes are directly exposed to
elevated FGF19 concentrations from bile, hence an
oncogenic role of bile-derived FGF19 is more plausi-
ble for cholangiocarcinoma.33
Of note, we demonstrated that hGBECs derived
from GBs of GSD patients expressed lower FGF19
transcripts than non-GSD controls, however, biliary
FGF19 content remained comparable in both groups
(Figure 3). GB bile FGF19 levels may not correlate
with GB cholangiocytes FGF19 mRNA levels be-
cause FGF19 derived from cholangiocytes of the int-
rahepatic biliary tree,28 is mixed and concentrated
with GB-derived FGF19 in the GB lumen. The find-
ing of a lower FGF19 mRNA level in GB cholangi-
ocytes of GSD patients is intriguing. Theoretically,
the secretion of biliary FGF19 could have a role on
gallstone pathogenesis by affecting GB motor func-
tion3 and/or BA metabolism. Alternatively, the re-
duced hGBECs FGF19 mRNA levels might occur
merely as a consequence of the local inflammatory
process frequently accompanying GB disease.
Besides biliary secretion of FGF19 by cholangi-
ocytes, the question remains whether hGBECs also
contribute to regional (hepatic) and/or systemic
FGF19 circulating levels and metabolic functions.
Currently, the best human model to test this hy-
pothesis is measuring the effect of GB resection on
FGF19 levels and some of its best-known metabolic
effects, such as regulation of BA homeostasis.7-10
The second finding of our study was that CCT in-
duced a pronounced increase in BA synthesis,
changes in the physiologic daily oscillations of BA
synthesis, and significantly altered the diurnal
FGF19 rhythm and reduced [FGF19]
s
 levels at
Figure 8. Linear correlation between FGF19 and C4 serum















































2.0 2.5 3.0 3.5
Log FGF19 (pg/mL)













BA synthesis and FGF19 levels after cholecystectomy. , 2015; 14 (5): 710-721
noon. Thus, these findings suggest that the GB ac-
tively participates in BA homeostasis and FGF19
circulating levels.
Our clinical study was carried out in a selected
cohort of GSD patients with small stones and
functioning GB’s, who underwent elective laparo-
scopic CCT. Since FGF19 levels and BA synthesis
show important inter-individual and circadian fluc-
tuations,34 we included serum samples of all subject
obtained at standardized time points (fasting and
post prandial), before and after CCT. All analysis
were performed on a strict pairwise basis. Accord-
ingly, the observed modifications of BA metabolism
and circulating FGF19 seem to be mediated either
directly or indirectly by CCT.
The fact that hGBECs secrete FGF19 into bile
(apical membrane sorting) does not exclude the pos-
sibility of simultaneous intracellular traffic of
FGF19 to the basolateral plasma membrane and se-
cretion into the systemic circulation. There are sev-
eral examples of hormones and proteins that present
a bidirectional secretion or destination including:
leptin in fundic stomach cells;35 angiotensin in prox-
imal tubular renal cells;36 and the HDL-cholesterol
receptor SR-BI, which is expressed in the basal
membrane of hepatocytes, but in the apical mem-
brane of hGBECs and enterocytes.18 Interestingly, a
clear apical signal for FGF19 was evident in the dis-
tal ileum enterocytes (Figure 1A), suggesting that
besides its sorting to the basolateral membrane,
FGF19 could also be transported to the apical mem-
brane and secreted into the intestinal lumen. Fur-
ther studies aimed to precisely define the
intracellular trafficking of FGF19 in cholangiocytes
and enterocytes are needed to clarify these issues.
The effect of CCT on BA synthesis was extensively
studied by the gold standard isotope dilution tech-
nique during the 70’s and 80’s, before the discovery
of FGF19. All these studies were performed in small
numbers of GSD patients that differed in gender, age,
and time points after surgery. The most recent study
designed to investigate the effect of CCT on BA kinet-
ics at time points similar to our study (6 weeks and 3
month) was published in 1989.37 While the effect of
CCT on BA synthesis, pool size and loss from the en-
terohepatic circulation have been controversial,34,38
the effect on BA fractional turnover rates has been
more consistent, showing an enhanced postoperative
enterohepatic cycling of BA.34 This means that the
absence of the GB decreases the sequestration of BA
pool in the biliary tree between meals, so that hepatic
bile secretion into the intestine is more continuous
and ileal BA concentration and exposure may there-
fore increase.39 In this scenario, we postulate that an
enhanced enterohepatic cycling of BA after CCT may
maintain a higher active FXR signaling in the gut
and a reduction of ileal FGF19 synthesis and secre-
tion is therefore unlikely. Based on our data, we pos-
tulate that the extraction of the GB is the main
factor determining the observed changes in diurnal
rhythm and reduction in [FGF19]
s
, presumably by
hampering the contribution of cholangocytes-derived
FGF19 to the circulation levels.
The markedly enhanced fasting BA synthesis
measured as C4 and observed as early as 2 weeks
and maintained 3 month after CCT is consistent
with previous reports using the same surrogate
marker of BA synthesis before and after CCT.10,34,40
These results are in apparent contradiction with
most studies performed using the isotope dilution
technique, in which no change of BA synthesis rates
after CCT was found, either at short34,37 or long
term41 after surgery. So, how can we explain this ap-
parent discrepancy? BA synthesis measured by the
isotope dilution technique reflects total daily BA
synthesis, whereas BA synthesis assessed by the C4
method reflects BA synthesis at a fixed point.
CYP7A1, the rate-limiting and major regulatory en-
zyme in the synthesis has a short life of 2-3 h. C4 in
peripheral blood mirrors the hepatic CYP7A1 enzy-
matic activity, and its half-life is also less than 5
h.34 Indeed, we observed that the diurnal level of C4
changes drastically after CCT, starting with 2-fold
higher fasting levels and a sustained decrease dur-
ing the day (Figure 6B). Unfortunately, because of
logistic reasons we were unable to assess C4 serum
levels during a 24 h period. The area under the
curve of C4 serum levels during our 8h protocol was
significantly greater 2 weeks and 3 month after CCT
compared to pre-CCT values (data not shown), but a
24h monitoring of C4 serum levels is needed to dem-
onstrate if BA synthesis assessed by this surrogate
marker may fit with data generated by the isotope
dilution assay.
In conclusion, GB expresses and secretes high levels
of FGF19. The expression level of FGF19 is lower in
GB cholangiocytes of GSD patients, but FGF19 con-
tent in GB bile remains similar. CCT changes
[FGF19]
s
 diurnal rhythm, reduces its noon levels, and
this intervention is coupled to a drastic increase in
fasting BA synthesis. Given that available knowledge
suggests that enterohepatic cycling of BA increases
several times after CCT, we postulate that the absence
of GB - and not ileal-derived FGF19 - may be responsi-
ble for this effect on circulating FGF19 and BA syn-
thesis. Since we have recently shown that CCT mice
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evolve with significant metabolic changes expressed by
increase serum and hepatic triglyceride concentrations
and hepatic VLDL production,42 and supra physiologic
levels FGF19 prevent diet induced hepatic steatosis in
mice,15 our results suggests that CCT may also have
major systemic metabolic effects in humans. Interest-
ingly in a recent epidemiologic study Ruhl, et al. dem-
onstrated that cholecystectomy was independently
associated to a significant increase in non-alcoholic
fatty liver disease even after adjusting for all the com-
mon risk factors associated with these diseases.43
Thus the generally accepted medical concept that CCT,
one of the most frequent surgeries performed world-
wide, is largely innocuous requires further systematic
evaluation.44
ABBREVIATIONS
 BA: bile acids.
 C4: 7a-hydroxy-4-cholesten-3-one.
 CA: cholic acid.
 CCT: cholecystectomy.
 CDCA: chenodeoxycolic acid.
 CI: confidence interval.
 CYP7A1: cytochrome p450 7A1.
 DCA: deoxycholate acid.
 DMEM: Dulbecco’s Modified Eagle Medium.
 DMSO: Dimethyl sulfoxide.
 FBS: fetal bovine serum.
 FGF15: fibroblast growth factor 15.
 FGF19: fibroblast growth factor 19.
 [FGF19]
s
: fibroblast growth factor 19 serum
concentration.
 FGFR: fibroblast growth factor receptor.
 FXR: farnesoid X receptor.
 GB: gallbladder.
 GSD: gallstone disease.
 hGBECs: human gallbladder epithelial cells.
 HPLC: high performance liquid chromatogra-
phy.
 IF: immunofluorescence assay.
 IH: immunohistochemistry assay.
 LCA: lithocholic acid.
 OR: odds ratio.
 SEM: standard error of mean.
 UDCA: ursodeoxycholate acid.
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